MARKET

PSTI

PSTI

Pluristem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.000
+0.040
+1.35%
After Hours: 3.090 +0.09 +3.00% 16:53 09/17 EDT
OPEN
2.930
PREV CLOSE
2.960
HIGH
3.060
LOW
2.920
VOLUME
141.17K
TURNOVER
--
52 WEEK HIGH
11.85
52 WEEK LOW
2.810
MARKET CAP
95.22M
P/E (TTM)
-1.7014
1D
5D
1M
3M
1Y
5Y
Innocan Pharma gained 350% in value this year Is it still a good time to buy? | BreezyScroll
Prospective investors should know that this is just the beginning, as according to financial analysts, InnoCan's stock surged due to the publication of its recent experimental trials. The exposure bolstered market confidence and now many notable experts ar...
MENAFN · 3d ago
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Sept. 10, 2021: IOVA, NSTG, U, NVDA, TRMB, IRDM, TTD, LC, CLLS, CRBU, DRNA, PSTG, PSTI, NVS, SPR
Iovance Biotherapeutics (IOVA) - 132,377  Nanostring Technologies (NSTG) - 55,617  Unity Software (U) - 138,794  Nvidia (NVDA) - 300 Trimble (TRMB) - 15,880  Iridium
Benzinga · 4d ago
InnoCan Pharma receives strong buy recommendation: Here is why
Those who invested in InnoCan Pharma's (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) a year ago are up 273%.
MENAFN · 09/10 19:24
Will Pluristem Therapeutics (NASDAQ:PSTI) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 09/01 15:01
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Aug. 30, 2021: IOVA, MCRB, ISRG, BABA, NXPI, GOOG, MELI, SE, PSTI, CLLS
Iovance Biotherapeutics (IOVA) - 71,749 Seres Therapeutics (MCRB) - 846,468 Intuitive Surgical (ISRG) - 1,700 Alibaba Group Golding (BABA) - 15,089 NXP Semiconductors (NXPI)
Benzinga · 08/31 14:57
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Aug. 27, 2021: MCRB, NSTG, IOVA, BABA, LC, OKTA, CLLS, PSTI, BMY
Seres Therapeutics (MCRB) - 1,282,095  NanoString Technologies (NSTG) - 66,400  Iovance Biotherapeutics (IOVA) - 444,050  Alibaba Group (BABA) - 13,593  LendingClub (LC)
Benzinga · 08/30 14:39
Cathie Wood's ARK Invest Posts Fund Sales For Thursday, Aug. 26, 2021: NTDOY, IOVA, NSTG, SE, XONE, BABA, LC, SQ, OKTA, MCRB, PSTI, SEER, RHHBY, BMY, GOOG, TRMB
Nintendo (NTDOY) - 38,500 Shares Iovance Biotherapeutics (IOVA) - 302,190 NanoString Technologies (NSTG) - 144,340 Sea (SE) - 71,593 ExOne (XONE) - 10,000 Alibaba (BABA) - 46,900 LendingClub (LC) - 32,700 Square
Benzinga · 08/27 13:16
Here’s how Cathie Wood’s stocks are doing and which ones are candidates for a late-year rebound
CNBC Pro screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.
CNBC.com · 08/26 19:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSTI. Analyze the recent business situations of Pluristem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PSTI stock price target is 9.08 with a high estimate of 12.50 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 83
Institutional Holdings: 4.66M
% Owned: 14.68%
Shares Outstanding: 31.74M
TypeInstitutionsShares
Increased
16
486.24K
New
15
745.22K
Decreased
8
2.33M
Sold Out
15
667.47K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Executive Director
Zalman Aberman
President/Chief Executive Officer/Director
Yaky Yanay
Chief Financial Officer/Treasurer/Secretary
Chen Franco-Yehuda
Lead Director/Independent Director
Doron Shorrer
Director
Doron Birger
Director
Rami Levy
Director
Varda Shalev
Director
Maital Shemesh-Rasmussen
Independent Director
Isaac Braun
Independent Director
Mark Germain
Independent Director
Moria Kwiat
No Data
About PSTI
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Webull offers kinds of Pluristem Therapeutics Inc. stock information, including NASDAQ:PSTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTI stock methods without spending real money on the virtual paper trading platform.